en · de · es · fr · pt
sr9009-notes.peptides6608.com › Faq › Mechanism And Preclinical Findings — Deep Dive

Mechanism And Preclinical Findings — Deep Dive

By Editorial Desk · published 2026-05-25 · last reviewed 2026-07-08 · Faq

REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

SR9009 Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

Related pages on this site

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Supporting material

=== Anticarcinogenic activity === The anticancer activity of bovine lactoferrin (bLF) has been demonstrated in experimental lung, bladder, tongue, colon, and liver carcinogeneses on rats, possibly by suppression of phase I enzymes, such as cytochrome P450 1A2 (CYP1A2). Also, in another experiment done on hamsters, bovine lactoferrin decreased the incidence of oral cancer by 50%. Currently, bLF is used as an ingredient in yogurt, chewing gums, infant formulas, and cosmetics.

1969), former editor of The Times; former director of BBC News; co-founder of Tortoise Media, news website co-founded with Matthew Barzun, a former U.S. Ambassador to the United Kingdom, which purchased The Observer in 2024 with the transfer taking place on 22 April 2025. Lee Harpin, ( b. 1967 ) In the late 1980s, Harpin regularly wrote for the iconic British style, music, and fashion magazines The Face and i-D; has also written for Daily Star, News of the World, Sunday People, Sunday Mirror, Daily Mirror, Mail on Sunday and Daily Mail, Jewish Chronicle, Political Editor at The Jewish News , Times of Israel, United with Israel ( UWI ). Ernest Abraham Hart Simon Hattenstone (born 29 December 1962 in Salford, England); journalist and writer; features writer and interviewer for The Guardian. He has also written or ghost-written a number of biographical books. Afua Hirsch (born 1981); of Ghanaian and German Jewish paternal lineage; has worked as a journalist for The Guardian newspaper, and Education Editor for Sky News; author of Brit(ish): On Race, Identity and Belonging; was on panel of judges for Booker Prize for Fiction; was included in 2020 edition of the Powerlist of the most influential Britons from African/African-Caribbean heritage; was cited as one of top 100 most influential Africans by New African; in Powerlist 2021, she made top 10, ranking ninth most influential person of African or African Caribbean heritage in United Kingdom; Hirsh is great-niece of noted scholar Peter Hirsch.

Necrotizing fasciitis (NF), also known as flesh-eating disease or flesh-eating bacteria, is an infection that kills the body's soft tissue. It is a serious disease that begins and spreads quickly. It is sometimes incorrectly labeled flesh-eating virus. Symptoms include red or purple or black skin, swelling, severe pain, fever, and vomiting. The most commonly affected areas are the limbs and perineum. Bacterial infection is by far the most common cause of necrotizing fasciitis. Despite being called a "flesh-eating disease", bacteria do not eat human tissue. Rather, they release toxins that cause tissue death. Typically, the infection enters the body through a break in the skin, such as a cut or burn. Risk factors include recent trauma or surgery and a weakened immune system due to diabetes or cancer, obesity, alcoholism, intravenous drug use, and peripheral artery disease. It does not usually spread between people. The disease is classified into four types, depending on the infecting organisms. Medical imaging is often helpful to confirm the diagnosis. Necrotizing fasciitis is treated with surgery to remove the infected tissue, and antibiotics. It is considered a surgical emergency. Delays in surgery are associated with a much higher risk of death. Despite high-quality treatment, the risk of death remains 25–35%.

Sources: en.wikipedia.org

Notes from published material

"Handout on Health: Back Pain". National Institute of Arthritis and Musculoskeletal and Skin Diseases. 10 April 2017. Qaseem A, Wilt TJ, McLean RM, Forciea MA (April 2017). "Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians". Annals of Internal Medicine. 166 (7): 514–30. doi:10.7326/M16-2367. PMID 28192789. "Non-specific Back Pain Guidelines" (PDF). Kaiser Foundation Health Plan of Washington. 2017. Archived from the original (PDF) on 14 January 2020.

=== Hydrolysis === Amides hydrolyse in hot alkali as well as in strong acidic conditions. Acidic conditions yield the carboxylic acid and the ammonium ion while basic hydrolysis yield the carboxylate ion and ammonia. The protonation of the initially generated amine under acidic conditions and the deprotonation of the initially generated carboxylic acid under basic conditions render these processes non-catalytic and irreversible. Electrophiles other than protons react with the carbonyl oxygen. This step often precedes hydrolysis, which is catalyzed by both Brønsted acids and Lewis acids. Peptidase enzymes and some synthetic catalysts often operate by attachment of electrophiles to the carbonyl oxygen.

=== TNXB (functional gene) === The TNXB gene localizes to the major histocompatibility complex (MHC class III) region on chromosome 6. The structure of this gene is unusual in that it overlaps the CREBL1 and CYP21A2 genes at its 5' and 3' ends, respectively.

Sources: en.wikipedia.org

Background from the literature

== Legality == The legality of AI-generated pornography remains an evolving issue. In some countries, laws concerning digital simulation may apply indirectly, particularly when the generated content features images of real people without their consent. Additionally, most existing laws regulate deepfake pornography of nonconsenting individuals, rather than fully synthesized AI pornography.

Beneš—the leader of the Czechoslovak government-in-exile—and František Moravec—head of Czechoslovak military intelligence—organized and coordinated a resistance network. Hácha, Prime Minister Alois Eliáš, and the Czechoslovak resistance acknowledged Beneš's leadership. Active collaboration between London and the Czechoslovak home front was maintained throughout the war years. The most important event of the resistance was Operation Anthropoid, the assassination of Reinhard Heydrich, SS leader Heinrich Himmler's deputy and the then Protector of Bohemia and Moravia. Infuriated, Hitler ordered the arrest and execution of 10,000 randomly selected Czechs. Over 10,000 were arrested, and at least 1,300 were executed. According to one estimate, 5,000 were killed in reprisals. The assassination resulted in one of the most well-known reprisals of the war. The Nazis completely destroyed the villages of Lidice and Ležáky; all men over 16 years from the village were murdered, and the rest of the population was sent to Nazi concentration camps where many women and nearly all the children were killed. The Czechoslovak resistance comprised four main groups:

Chronic poisoning is long-term repeated or continuous exposure to a poison where symptoms do not occur immediately or after each exposure. The person gradually becomes ill, or becomes ill after a long latent period. Chronic poisoning most commonly occurs following exposure to poisons that bioaccumulate, or are biomagnified, such as mercury, gadolinium, and lead.

== External links == "Formylpeptide Receptors: FPRL1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Network